Acylated and unacylated ghrelin dosages
( DrugBank: - / KEGG DRUG: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 1 |
| 201 | Angelman syndrome | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 202 | Smith-Magenis syndrome | 1 |
193. Prader-Willi syndrome
Clinical trials : 128 / Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
201. Angelman syndrome
Clinical trials : 33 / Drugs : 32 - (DrugBank : 13) / Drug target genes : 22 - Drug target pathways : 21
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
202. Smith-Magenis syndrome
Clinical trials : 9 / Drugs : 8 - (DrugBank : 3) / Drug target genes : 3 - Drug target pathways : 4
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|